Results 261 to 270 of about 126,024 (329)

Cost-effectiveness analysis of anlotinib plus penpulimab versus sorafenib in the treatment of unresectable hepatocellular carcinoma. [PDF]

Hum Vaccin Immunother
Luo J, Li Z, Gui C, Du Q, Liu J.
europepmc   +1 more source

Economic evaluation of anlotinib plus penpulimab vs. sorafenib as first-line therapy for unresectable hepatocellular carcinoma in China. [PDF]

Front Public Health
Fang R, Liang J, Wang T, Sheng F, Xu J.
europepmc   +1 more source

Neuropilin-2 (NRP2) mediates sorafenib resistance in clear cell renal cell carcinoma via the NRP2/NF-κB/TNFα axis. [PDF]

Am J Cancer Res
Gu R, Long Q, He T, Li W, Zhang Z, Zhang T, Xu D, Li Z, Liu Q.   +8 more
europepmc   +1 more source

Hsa-miR-423-5p selectively loaded in hypoxic exosomes reduces the sensitivity of normoxic hepatocellular carcinoma to sorafenib via autophagy. [PDF]

Cancer Cell Int
Shu B, Zou M, Liao R, Wen D, Gao X, Lu J, Song H, Sheng Z, Liu Z, You Y.   +9 more
europepmc   +1 more source

Comprehensive bioinformatic analysis reveals sorafenib response-related prognostic signature in hepatocellular carcinoma. [PDF]

J Gastrointest Oncol
Zhao Y, Dong J, Zhong H, Peng L, Wu L, Yu M, Ding G, Guo W.   +7 more
europepmc   +1 more source

Additional file 10 of Corynoline enhances sorafenib sensitivity in hepatocellular carcinoma via NOS3-mediated ROS production

Yi, Qiaoli, Chen, Xi, Zhou, Shangjun, Wang, Jiayu, Yan, Yuanliang   +4 more
openalex   +1 more source

Nivolumab plus ipilimumab versus lenvatinib or sorafenib for US and Chinese patients with unresectable hepatocellular carcinoma: a cost-effectiveness analysis. [PDF]

Front Public Health
Wu Q, Qin Y, Li Q.
europepmc   +1 more source

Past, present, and future of immunotherapy research in liver neoplasms: A bibliometric and visualization analysis. [PDF]

Medicine (Baltimore)
Ma W, Wang L, Niu Y, Nie Z.
europepmc   +1 more source

Real-World Comparison of Lenvatinib and Sorafenib as First-Line Treatments for Hepatocellular Carcinoma: A Multicenter Study. [PDF]

J Hepatocell Carcinoma
Kang M, Cha WC, Sinn DH, Jeong WK, Kim DY, Lee MJ, Lim S, Kim D, Kim KP, Ryoo BY, Choi WM, Kim KM, Kim KH, Lee D, Choi EJ, Jung C, Kim J, Hong JY.   +17 more
europepmc   +1 more source